CDK14 and neoplasm: One propagated tumor line, CBP1, from a model ES cell line overexpressing CDK14 in addition to β-Catenin was tested to assess whether a propagatable colon tumor lacking KRAS activation and CDK6 amplification would respond to either of the targeted agents or their combination.